JP7599425B2 - トランスフェリン受容体結合分子、そのコンジュゲート、及びその使用 - Google Patents

トランスフェリン受容体結合分子、そのコンジュゲート、及びその使用 Download PDF

Info

Publication number
JP7599425B2
JP7599425B2 JP2021540103A JP2021540103A JP7599425B2 JP 7599425 B2 JP7599425 B2 JP 7599425B2 JP 2021540103 A JP2021540103 A JP 2021540103A JP 2021540103 A JP2021540103 A JP 2021540103A JP 7599425 B2 JP7599425 B2 JP 7599425B2
Authority
JP
Japan
Prior art keywords
vhh
seq
molecule
tfr
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021540103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518392A5 (https=
JP2022518392A (ja
Inventor
ロミー コーエン，
マリオン ダヴィド，
ミシェル クレストシャティスキ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aix Marseille Universite
Vect Horus
Original Assignee
Aix Marseille Universite
Vect Horus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aix Marseille Universite, Vect Horus filed Critical Aix Marseille Universite
Publication of JP2022518392A publication Critical patent/JP2022518392A/ja
Publication of JP2022518392A5 publication Critical patent/JP2022518392A5/ja
Application granted granted Critical
Publication of JP7599425B2 publication Critical patent/JP7599425B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2021540103A 2019-01-09 2020-01-08 トランスフェリン受容体結合分子、そのコンジュゲート、及びその使用 Active JP7599425B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305031.7 2019-01-09
EP19305031 2019-01-09
PCT/EP2020/050318 WO2020144233A1 (en) 2019-01-09 2020-01-08 Transferrin receptor-binding molecules, conjugates thereof and their uses

Publications (3)

Publication Number Publication Date
JP2022518392A JP2022518392A (ja) 2022-03-15
JP2022518392A5 JP2022518392A5 (https=) 2022-12-19
JP7599425B2 true JP7599425B2 (ja) 2024-12-13

Family

ID=65236972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021540103A Active JP7599425B2 (ja) 2019-01-09 2020-01-08 トランスフェリン受容体結合分子、そのコンジュゲート、及びその使用

Country Status (9)

Country Link
US (1) US12152317B2 (https=)
EP (1) EP3908608A1 (https=)
JP (1) JP7599425B2 (https=)
CN (1) CN113474369B (https=)
AU (1) AU2020206593B2 (https=)
BR (1) BR112021013559A2 (https=)
CA (1) CA3124790A1 (https=)
EA (1) EA202191893A1 (https=)
WO (1) WO2020144233A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12258597B2 (en) 2018-02-07 2025-03-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
US20240391967A1 (en) * 2020-12-02 2024-11-28 University Health Network Methods and uses for ndfip1 fusion polypeptides in treating neurodegenerative diseases, brain and/or traumatic and non-traumatic spinal cord injuries, and/or optic neuropathies
MX2024005968A (es) * 2021-11-19 2024-08-06 Japan Chem Res Peptido que tiene afinidad por el receptor de transferrina humano.
CN117377487B (zh) 2021-12-02 2024-11-22 领诺(上海)医药科技有限公司 转铁蛋白结合抗体及其应用
US11939391B2 (en) * 2021-12-06 2024-03-26 MedAbome, Inc. Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment
WO2023128702A1 (ko) * 2021-12-31 2023-07-06 주식회사 아임뉴런 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
CN119301262A (zh) 2022-04-01 2025-01-10 武田药品工业株式会社 用于具有cns表现的疾病的基因疗法
EP4526344A1 (en) * 2022-05-16 2025-03-26 Denali Therapeutics Inc. Transferrin receptor-binding domains and proteins comprising the same
CN120659627A (zh) * 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
KR20250111123A (ko) 2022-11-23 2025-07-22 키2브레인 에이비 Vhh 항체 및 이의 용도
US20260116990A1 (en) 2022-11-23 2026-04-30 Key2Brain Ab Vhh antibodies and uses thereof
AU2023404617A1 (en) * 2022-12-02 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-tfr1 antibodies and uses thereof
TW202436352A (zh) * 2023-02-07 2024-09-16 日商Ｊｃｒ製藥股份有限公司 人類運鐵蛋白受體親和性肽
CN116179607A (zh) * 2023-03-27 2023-05-30 迦进生物医药(上海)有限公司 一种human TfR2高表达的稳转细胞株及其构建方法和应用
CN116121306A (zh) * 2023-03-27 2023-05-16 迦进生物医药(上海)有限公司 一种human TfR1高表达的稳转细胞株及其构建方法和应用
AU2024243709A1 (en) 2023-04-03 2025-11-06 Katholieke Universiteit Leuven Blood-brain barrier crossing antibodies
CN121794291A (zh) 2023-06-22 2026-04-03 维克塔-霍洛斯公司 转铁蛋白受体结合分子、其偶联物及其用于预防或治疗肌肉疾病的用途
EP4731658A1 (en) 2023-06-22 2026-04-29 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat nervous system diseases
EP4480964A1 (en) 2023-06-22 2024-12-25 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases
EP4480965A1 (en) 2023-06-22 2024-12-25 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat cns diseases
CN121773136A (zh) * 2023-07-04 2026-03-31 北京星奇原生物科技有限公司 抗-TfR1抗体及其用途
WO2025042711A1 (en) 2023-08-18 2025-02-27 Eli Lilly And Company Engineered transferrin receptor binding peptides as well as methods of making and using the same
US20250064958A1 (en) * 2023-08-22 2025-02-27 Eli Lilly And Company AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENTS
WO2025194170A1 (en) * 2024-03-15 2025-09-18 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization and degradation of immune-related membrane proteins
WO2025194171A1 (en) * 2024-03-15 2025-09-18 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization and degradation of g protein-coupled receptors
WO2025207959A1 (en) * 2024-03-27 2025-10-02 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
WO2025207946A1 (en) * 2024-03-28 2025-10-02 Genzyme Corporation Polypeptides binding to a specific epitope of the transferrin receptor 1
WO2025226642A1 (en) 2024-04-25 2025-10-30 Eli Lilly And Company Lipid nano delivery particles for targeted transport of nucleic acids and methods of making and using the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057445A1 (en) 2000-05-26 2002-07-25 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
JP2010533130A (ja) 2007-06-29 2010-10-21 インスティティ・パスツール 目的物質の送達用ペプチドベクターの製造のためのｖｈｈ抗体の使用及びその適用
JP2014500866A (ja) 2010-11-05 2014-01-16 ライナット ニューロサイエンス コーポレイション 操作されたポリペプチドコンジュゲートおよびトランスグルタミナーゼを用いてそれを作製する方法
JP2016501881A (ja) 2012-12-04 2016-01-21 アッヴィ・インコーポレイテッド 血液脳関門（ｂｂｂ）を透過する二重特異性結合タンパク質
WO2018031424A1 (en) 2016-08-06 2018-02-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2207568B1 (en) 2007-11-16 2017-05-31 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
FR2959229B1 (fr) 2010-04-21 2013-01-18 Vect Horus Derives peptidiques, leur preparation et leurs utilisations
CA2818173C (en) 2010-11-30 2022-05-03 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
WO2013177062A2 (en) 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
CN105102478A (zh) * 2013-01-30 2015-11-25 弗拉芒区生物技术研究所 用于筛选和药物发现目的的新型嵌合多肽
EP2899208A1 (en) * 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
NZ724869A (en) * 2014-03-06 2022-07-01 Nat Res Council Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
EP3218411B1 (en) 2014-11-14 2022-01-12 Ossianix, Inc. Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
EA039366B1 (ru) 2015-06-24 2022-01-19 Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057445A1 (en) 2000-05-26 2002-07-25 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
JP2010533130A (ja) 2007-06-29 2010-10-21 インスティティ・パスツール 目的物質の送達用ペプチドベクターの製造のためのｖｈｈ抗体の使用及びその適用
JP2014500866A (ja) 2010-11-05 2014-01-16 ライナット ニューロサイエンス コーポレイション 操作されたポリペプチドコンジュゲートおよびトランスグルタミナーゼを用いてそれを作製する方法
JP2016501881A (ja) 2012-12-04 2016-01-21 アッヴィ・インコーポレイテッド 血液脳関門（ｂｂｂ）を透過する二重特異性結合タンパク質
WO2018031424A1 (en) 2016-08-06 2018-02-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use

Also Published As

Publication number Publication date
WO2020144233A1 (en) 2020-07-16
CN113474369A (zh) 2021-10-01
EP3908608A1 (en) 2021-11-17
BR112021013559A2 (pt) 2021-09-21
JP2022518392A (ja) 2022-03-15
US12152317B2 (en) 2024-11-26
US20220090050A1 (en) 2022-03-24
CN113474369B (zh) 2024-09-03
EA202191893A1 (ru) 2021-12-02
CA3124790A1 (en) 2020-07-16
AU2020206593B2 (en) 2026-02-05
AU2020206593A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
JP7599425B2 (ja) トランスフェリン受容体結合分子、そのコンジュゲート、及びその使用
Stocki et al. Blood‐brain barrier transport using a high affinity, brain‐selective VNAR antibody targeting transferrin receptor 1
US11273206B2 (en) Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptides
JP6541237B2 (ja) インスリン様成長因子１受容体特異的抗体及びそれらの使用
JP6541235B2 (ja) インスリン様成長因子１受容体特異的抗体及びそれらの使用
US20230414780A1 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses
US12037382B2 (en) Inverse agonistic anti-US28 antibodies
US20260062480A1 (en) Human blood-brain barrier targeting antibodies
US20240174755A1 (en) Platelet derived growth factor receptor (pdgfr) antibodies, conjugates, compositions, and uses thereof
EP4480965A1 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat cns diseases
US20240325562A1 (en) Internalizing binding molecules
US12161889B2 (en) Blood brain barrier (BBB)-selective antibodies and methods of use thereof to target agents to the BBB
EA048741B1 (ru) Молекулы, связывающие рецептор трансферрина, их конъюгаты, и их применение
EP4731658A1 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat nervous system diseases
US20250352660A1 (en) Blood-nerve barrier targeting conjugates and methods of use
CN118139627A (zh) 使car t细胞恢复活力的缀合物、组合物和方法
JP2026512773A (ja) Ｒａｇｅ受容体結合分子、そのコンジュゲート、および、肺疾患を検出、予防または治療するためのその使用
CN121794291A (zh) 转铁蛋白受体结合分子、其偶联物及其用于预防或治疗肌肉疾病的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240806

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241203

R150 Certificate of patent or registration of utility model

Ref document number: 7599425

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150